BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE

VolverGo back

Resultados 52 results. LastUpdate Updated on 23/10/2020 [19:14:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



previousPage Page2/3 nextPage   results/page


METHODS OF PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH INFLAMMATORY BOWEL DISEASE

Publication No.: US2020231690A1 23/07/2020

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

TW_201842191_A

Absstract of: US2020231690A1

The aspects disclosed herein describe methods of identifying a subject that is non-responsive to anti-TNF therapy. The aspects disclosed herein further provide for a method of selecting a therapy for a subject with Inflammatory Bowel Disease (IBD), and treating the subject with the therapy.

traducir

METHODS OF TREATING DISEASES

Publication No.: EP3677597A1 08/07/2020

Applicant:

BOEHRINGER INGELHEIM INT [DE]

US_2020299378_A1

Absstract of: EP3677597A1

This invention generally relates to methods for the treatment of IL-23 related diseases, in particular inflammatory diseases, such as Crohn's Disease, utilizing anti-IL-23A antibodies.

traducir

SINGLE IMMUNOGLOBULIN INTERLEUKIN-1 RECEPTOR RELATED (SIGIRR) VARIANTS AND USES THEREOF

Publication No.: CN111373053A 03/07/2020

Applicant:

REGENERON PHARMA

KR_20200058435_A

Absstract of: CN111373053A

The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based onthe identification of such alterations in the nucleic acid molecules encoding SIGIRR.

traducir

GP2 ISOFORMS AND THEIR USE IN AUTOANTIBODY CAPTURE

Publication No.: US2020209258A1 02/07/2020

Applicant:

GA GENERIC ASSAYS GMBH [DE]

Absstract of: US2020209258A1

The invention relates to a method for binding or capturing autoantibodies directed to various Glycoprotein 2 (GP2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of GP2. The invention is characterized by the provision of multiple isoforms of GP2 as autoantibody targets and encompasses the practical utilization of the finding that the isoform specificity of anti-GP2 autoantibodies enables determination of particular autoimmune diseases. The invention also provides a system and kit developed for carrying out the claimed method. The present invention is useful for determining whether a sample from an individual comprises autoantibodies associated with an autoimmune disease, and for differentiating between multiple autoimmune diseases that exhibit similar symptoms, such as Celiac disease (CeD), Crohn's disease (CD), primary sclerosing cholangitis (PSC), and/or ulcerative colitis (UC).

traducir

METHODS OF TREATING INFLAMMATORY BOWEL DISEASES THAT TARGET RIPK2

Publication No.: WO2020139748A1 02/07/2020

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

Absstract of: WO2020139748A1

Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis in a subject, with an antagonist of RIPK2 activity or expression. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with the antagonist to RIPK2 activity or expression, as described herein.

traducir

DEVELOPMENT OF MICROBIAL BIOSENSORS FOR INTESTINAL INFLAMMATION

Publication No.: US2020209261A1 02/07/2020

Applicant:

BAYLOR COLLEGE MEDICINE [US]

WO_2018209318_A2

Absstract of: US2020209261A1

Embodiments of the disclosure include systems, methods, and compositions for detection of imminent onset of a symptom of a gut inflammation medical condition. The disclosure also concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual with IBD.

traducir

Irritable bowel syndrome serum metabolism marker combination and diagnostic kit thereof

Publication No.: CN111351870A 30/06/2020

Applicant:

KMBGI TECH CO LTD

Absstract of: CN111351870A

The invention discloses an irritable bowel syndrome serum metabolism marker combination. The irritable bowel syndrome serum metabolism marker combination can be used for in vitro diagnosis of the irritable bowel syndrome and can assist a clinician in judging whether a patient suffers from the irritable bowel syndrome or not, and the metabolic markers are expected to be applied to treatment targetsof the irritable bowel syndrome, so that the treatment effect of a clinical patient is improved. The invention also discloses a diagnostic kit for irritable bowel syndrome. The kit is constructed onthe basis of the principle that abundance data is analyzed by a liquid chromatography-mass spectrometry metabonomics analysis method on serum samples of positive control and negative control. It is verified that the kit has a high detection rate and high accuracy, can comprehensively reflect the serum metabolism marker difference condition of patients with irritable bowel syndrome, can be used forearly discovery of irritable bowel syndrome, strives for time for patients, starts treatment as soon as possible, and improves the clinical treatment effect.

traducir

Antigen associated with inflammatory bowel disease

Publication No.: CN111329994A 26/06/2020

Applicant:

PHILOGEN SPA

ES_2743423_T3

Absstract of: CN111329994A

The invention provides specific binding members of ED-A isoforms that bind fibronectin. The specific binding members can be used for treatment, diagnosis, detection and/or photographic methods for inflammatory bowel disease (IBD), and/or used for delivering a molecule conjugated to the specific binding member to IBD tissue. The specific binding member provided by the invention can be conjugated, for example, to an immunosuppressive or anti-inflammatory molecule, such as interleukin-10.

traducir

Novel application of C60 and product activity detection method thereof

Publication No.: CN111329882A 26/06/2020

Applicant:

LI XINRONG

Absstract of: CN111329882A

The invention discloses a novel application of C60 and a product activity detection method thereof, and belongs to the field of functional products. The new application mainly relates to an application of C60 in preparation of anti-inflammatory products, beauty products and health products. The C60 (Carbon-60) achieves the anti-inflammatory and anti-inflammatory pain and pruritus effects by inhibiting human neutrophil secretion TNF-alpha and inhibiting human neutrophil migration; and the C60 acts on skin mucosa to generate a certain anti-inflammatory or beauty effect, and the C60 has a slightinhibition effect on human neutrophil phagocytic foreign matters. The C60 product has an obvious improvement effect on release, migration and phagocytosis related diseases of human neutrophil TNF-alpha such as intractable skin pruritus, colitis, pruritus caused by mosquito bites, external auditory canal pruritus related to earwax, hemorrhoids, head neuralgia, pain caused by herpes zoster, chronictendon injury, muscle fascia pain and/or arthralgia, has the effects of whitening and thinning the face, and can improve blood circulation.

traducir

Application of gene Bmal1 in preparation of product for detecting inflammatory bowel diseases

Publication No.: CN111304316A 19/06/2020

Applicant:

UNIV SUZHOU

Absstract of: CN111304316A

The invention discloses application of a gene Bmal1 in preparation of a product for detecting and treating inflammatory bowel diseases, and belongs to the technical field of biomedicine. The inventiondiscloses the application of the gene Bmal1 in the preparation of the product for detecting and treating the inflammatory bowel diseases. The invention discovers, from an aspect of intestinal epithelial lymphocytes, that a certain Breg cell for highly expressing PDL1 is capable of inhibiting enteritis and cannot be regulated and controlled due to biological clock anomaly, and then, occurrence anddevelopment of the enteritis are promoted. The invention further illuminates a molecular mechanism, for regulating and controlling the Breg cell, of the gene Bmal1, so that more bases are provided for research and development of drugs targeting the gene Bmal1 and treatment of clinical inflammatory bowel diseases.

traducir

Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease

Publication No.: AU2020203468A1 18/06/2020

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

US_2018196063_A1

Absstract of: AU2020203468A1

The present invention describes methods, assays, and systems of diagnosing, selecting and treating irritable bowel syndrome (IBS) based on a subject's level of anti-vinculin and anti CdtB antibodies. IBS can be distinguished from inflammatory bowel (IBD) disease using the methods, assays, and systems described herein.

traducir

MARKERS FOR DISEASE AND DISEASE EXTENT IN INFLAMMATORY BOWEL DISEASE

Publication No.: US2020191803A1 18/06/2020

Applicant:

UNIV OTTAWA [CA]

CA_3067062_A1

Absstract of: US2020191803A1

A method for determining a presence of inflammatory bowel disease in a subject. The method involves providing a gut sample obtained from a subject; measuring a level in said gut sample of one or more proteins, wherein said one or more proteins comprises at least one of: leukotriene A-4 hydrolase, catalase, transketolase, thioredoxin domain containing protein 17, vasodilator-stimulated phosphoprotein and thymosin beta-10; and comparing said measured level of each of said one or more proteins to a corresponding protein level for a normal subject. A method for determining a presence of pancolitis in a subject with ulcerative colitis is also provided.

traducir

MITIGATION AND REVERSAL OF FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION AND RELATED SIGNALING PATHWAYS

Publication No.: US2020190203A1 18/06/2020

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

JP_2020033379_A

Absstract of: US2020190203A1

The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.

traducir

Application of PFOR protein specific IgA antibody as ulcerative colitis diagnostic marker

Publication No.: CN111273038A 12/06/2020

Applicant:

LI MING
WANG KAIRUO

Absstract of: CN111273038A

The invention provides application of a PFOR protein specific IgA antibody as an ulcerative colitis diagnostic marker, and belongs to the technical field of disease diagnosis. The method comprises thefollowing steps: screening a clostridium pullulans surface antigen, cloning, expressing and purifying the PFOR protein, and detecting the PFOR protein specific IgA antibody in the excrement of a patient according to an ELISA experimental principle. Research finds that compared with healthy people, the PFOR protein specific IgA antibody in excrement of patients with ulcerative colitis is obviouslyincreased and has significant difference. Therefore, the a PFOR protein specific IgA antibody can be used as a diagnostic marker for ulcerative colitis, so that clinical diagnosis and treatment and curative effect evaluation are facilitated, and the PFOR protein specific IgA antibody has good practical application value.

traducir

DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES

Publication No.: JP2020091296A 11/06/2020

Applicant:

DYAX CORP

AU_2020200423_A1

Absstract of: JP2020091296A

To provide methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis.SOLUTION: A method of diagnosing an autoimmune disease in a subject is provided, the method comprising: providing a biological sample of a subject suspected of having the autoimmune disease; measuring a level of cleaved high molecular weight kininogen (HMWK) in the biological sample; and identifying the subject as having or being at risk of developing the autoimmune disease if the level of cleaved HMWK in the biological sample is elevated as compared to that in a control sample.SELECTED DRAWING: Figure 1

traducir

ASSESSMENT AND MONITORING OF MUCOSAL HEALING IN CHILDREN AND ADULTS WITH CROHN'S DISEASE

Publication No.: WO2020117795A1 11/06/2020

Applicant:

PROMETHEUS BIOSCIENCES INC [US]

Absstract of: WO2020117795A1

Provided are methods for assessing or monitoring mucosal healing in an adult or pediatric patient with Crohn's Disease (CD). Some embodiments include receiving or detecting levels of biomarkers. In some embodiments, the biomarkers include Ang1, Ang2, CEACAM1, VCAM1, TGFα, CRP, SAA1, MMP-1, MMP-2, MMP-3, MMP-9, EMMPRIN, or IL-7. Some embodiments include applying a mathematical algorithm to the biomarker levels to produce a Endoscopic Healing Index (EHI) score for the adult or pediatric patient.

traducir

COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE

Publication No.: US2020181244A1 11/06/2020

Applicant:

CORIXA CORP [US]

US_2018362622_A1

Absstract of: US2020181244A1

Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.

traducir

METHOD OF DIAGNOSING A DYSBIOSIS

Publication No.: US2020181674A1 11/06/2020

Applicant:

SMARTDNA PTY LTD [AU]

JP_2020527055_A

Absstract of: US2020181674A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

traducir

BIOMARKERS FOR ASSESSING THE RESPONSE STATUS FOR TREATMENT OF INFLAMMATORY CONDITION OR DISEASE AFFECTING THE DIGESTIVE TRACT SUCH AS INFLAMMATORY BOWEL DISEASE IN HUMAN PATIENTS

Publication No.: US2020181706A1 11/06/2020

Applicant:

OSE IMMUNOTHERAPEUTICS [FR]
CT HOSPITALIER UNIVERSITAIRE NANTES [FR]

WO_2019025624_A1

Absstract of: US2020181706A1

The invention relates to the identification of biomarkers of the response status of a patient for a treatment with anti-TNFalpha agents, for treatment with anti-α4β7 agents or with both anti-TNFalpha agent and anti-α4β7 agents and to their use in assessing such status, in particular for assessing nonresponsive status for a treatment with anti-TNFalpha agents or respectively with anti-α4β7 agent in human patients suffering from inflammatory condition or disease, in particular Inflammatory Bowel Disease (IBD), in particular Ulcerative Colitis or Crohn's disease. The invention describes a method of in vitro assessing whether a treatment with anti-TNFalpha agent or with anti-α4β7 agent may be useful in a human patient suffering from inflammatory condition or disease, in particular when said condition or disease is a chronic and/or relapsing one, particularly a gastrointestinal, more particularly intestinal, inflammatory condition or disease which is eligible for treatment with anti-TNFalpha agent or respectively with anti-α4β7 agent. In a specific embodiment the method is suitable to assess whether such patient would be non-responsive to treatment with such anti-TNFalpha agent or respectively with anti-α4β7 agent and comprising determining a molecular signature in a biological sample previously obtained from said human patient.

traducir

LACTIC ACID BACTERIUM OF SPECIES LACTOBACILLUS PLANTARUM ISOLATED FROM CRUCIAN CARP SUSHI AND METHOD FOR SCREENING SAME

Publication No.: WO2020116365A1 11/06/2020

Applicant:

NIPPON SUISAN KAISHA LTD [JP]

Absstract of: WO2020116365A1

[Problem] To provide a novel lactic acid bacterium having a high functionality that is isolated from crucian carp sushi. [Solution] Provided is a lactic acid bacterium belonging to the species Lactobacillus plantarum, which is isolated from crucian carp sushi and has at least one effect selected from the group consisting of effects of inhibiting viral infection, enhancing NK activity, reducing lipids, lowering blood neutral fat level and improving bowel movement. Also provided is a lactic acid bacterium that is Lactobacillus plantarum subsp. plantarum FS-1C strain.

traducir

METHODS OF STRATIFYING AND TREATING A SUB-POPULATION OF INFLAMMATORY BOWEL DISEASE PATIENTS

Publication No.: WO2020113116A1 04/06/2020

Applicant:

CEDARS SINAI MEDICAL CENTER [US]

Absstract of: WO2020113116A1

Described herein are methods and systems for identifying subpopulations of patients having Crohn ́s disease, including populations at risk of developing structuring or other severe disease, and populations susceptible to success or failure with surgical intervention. Further provided are therapies useful for treating subpopulations of patients having Crohn ́s disease.

traducir

METHODS AND USES OF INFLAMMATORY BOWEL DISEASE BIOMARKERS

Publication No.: CN111212851A 29/05/2020

Applicant:

UNIV WASHINGTON

AU_2018304283_A1

Absstract of: CN111212851A

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1(PAI-1) inhibitor or tissue plasminogen activator (tPA).

traducir

CAPTURING CROWD WISDOM IN INDIVIDUALIZED TREATMENT PLANS

Publication No.: US2020168315A1 28/05/2020

Applicant:

VIVANTE HEALTH INC [US]

Absstract of: US2020168315A1

Embodiments of the invention include systems and methods for capturing crowd wisdom to be tested for individualized treatment plans. These systems and methods include data mining crowd sourced health related information and unstructured medical narratives and storytelling to identify treatment plans and general techniques that individuals with chronic diseases/symptoms, including but not limited to IBD and other immune invisible neglected and stigmatized diseases, use to improve their general health and wellbeing. A system for testing the treatments effectiveness in a population and then in an individual is also disclosed.

traducir

METHODS AND USES OF INFLAMMATORY BOWEL DISEASE BIOMARKERS

Publication No.: US2020165677A1 28/05/2020

Applicant:

STAPPENBECK THADDEUS [US]
KAIKO GERARD [US]
LIU TA CHIANG [US]

Absstract of: US2020165677A1

Among the various aspects of the present disclosure is the provision of methods of diagnosing and treating inflammatory bowel disease (IBD) including ulcerative colitis (UC) or Crohn's disease (CD). In particular, the present disclosure provides in part a panel of IBD biomarkers useful in diagnosing and making treatment decisions. In addition, the present disclosure provides methods of treating IBD with a plasminogen activator inhibitor-1 (PAI-1) inhibitor or tissue plasminogen activator (tPA).

traducir

USE OF BACTERIAL EXTRACELLULAR VESICLES AS A BIOMARKER FOR INTESTINAL BARRIER PERMEABILITY AND MICROBIAL DYSBIOSIS

Nº publicación: WO2020104577A1 28/05/2020

Applicant:

UNIV GENT [BE]

Absstract of: WO2020104577A1

The present invention relates to a method of analyzing a biofluid of a subject for the presence of bacterial extracellular vesicles (EV), said method comprising the steps of a) extracting bacterial EV from said biofluid, b) analyzing said bacterial EV-extracted molecular patterns for the presence of a disease marker, wherein said disease marker is a disease-specific molecular pattern of said subject; and said subject comprising patients diagnosed with HIV, IBD or cancer or said subject receiving a treatment.

traducir

previousPage Page2/3 nextPage results/page

punteroimgGo back